MCID: NVS001
MIFTS: 52

Neovascular Glaucoma

Categories: Eye diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neovascular Glaucoma

MalaCards integrated aliases for Neovascular Glaucoma:

Name: Neovascular Glaucoma 12 58 15 17
Glaucoma, Neovascular 44 71
Secondary Angle-Closure Glaucoma with Rubeosis 12
Glaucoma Neovascular 54

Characteristics:

Orphanet epidemiological data:

58
neovascular glaucoma
Prevalence: 1-5/10000 (Europe);

Classifications:

Orphanet: 58  
Rare eye diseases
Developmental anomalies during embryogenesis


External Ids:

Disease Ontology 12 DOID:1687
MeSH 44 D015355
SNOMED-CT 67 193564003
MESH via Orphanet 45 D015355
UMLS via Orphanet 72 C0017609
Orphanet 58 ORPHA94058
UMLS 71 C0017609

Summaries for Neovascular Glaucoma

Disease Ontology : 12 A glaucoma characterized by narrowing of the anterior chamber angle secondary to neovascularization along the iris and iridocorneal angle such that the aqueous fluid outflow is blocked and intraocular pressure becomes inappropriately elevated leading to optic nerve damage and visual field loss. Neovascular glaucoma has symptom progressive peripheral vision loss, decreased vision, and pain, redness, and headache in acute cases. Neovascular glaucoma can be related to abnormal angiogenesis with ischemic retinal diseases, inflammation, diabetes mellitus, intraocular malignancy, and autoinmmune diseases.

MalaCards based summary : Neovascular Glaucoma, also known as glaucoma, neovascular, is related to intraocular pressure quantitative trait locus and rubeosis iridis, and has symptoms including progressive peripheral vision loss An important gene associated with Neovascular Glaucoma is VEGFA (Vascular Endothelial Growth Factor A), and among its related pathways/superpathways are ERK Signaling and GPCR Pathway. The drugs Ranibizumab and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are glaucoma and visual loss

Related Diseases for Neovascular Glaucoma

Diseases related to Neovascular Glaucoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 258)
# Related Disease Score Top Affiliating Genes
1 intraocular pressure quantitative trait locus 31.8 VEGFA TGFB2 MYOC CRYAA
2 rubeosis iridis 31.4 VEGFA PLG
3 retinal vein occlusion 31.1 VEGFA KDR CXCL8
4 branch retinal artery occlusion 30.9 VEGFA PLG CRYAA
5 uveitis 30.9 TGFB2 CXCL8 CRYAA CAPN5
6 central retinal artery occlusion 30.8 VEGFA PLG CRYAA
7 retinal detachment 30.7 VEGFA RS1 FGF2 CXCL8 CAPN5
8 ocular hypertension 30.6 TGFB2 MYOC CRYAA
9 microvascular complications of diabetes 1 30.5 VEGFA TGFB2 PGF FLT1 FGF2 CXCL8
10 glaucoma, primary open angle 30.5 VEGFA TGFB2 MYOC CRYAA
11 melanoma, uveal 30.4 VEGFA TGFB2 PLG CRYAA
12 open-angle glaucoma 30.4 VEGFA TGFB2 MYOC CXCL8 CRYAA
13 cataract 30.3 VEGFA TJP1 TGFB2 FGF2 CXCL8 CRYAA
14 coats disease 30.2 VEGFA RS1 KDR
15 microvascular complications of diabetes 5 29.9 VEGFA TGFB2 PLG PGF KDR FLT1
16 endophthalmitis 29.8 VEGFB VEGFA PLG PGF FLT1 CXCL8
17 keratitis, hereditary 29.6 VEGFA MYOC FLT1 FGF2 CXCL8 CRYAA
18 macular holes 29.5 VEGFA TGFB2 RS1 PLG CXCL8 CRYAA
19 malignant ciliary body melanoma 29.5 VEGFD KDR FLT1
20 hemangioma 29.5 VEGFA KDR FLT1 FGF2
21 retinal artery occlusion 29.5 VEGFB VEGFA PLG PGF KDR FLT1
22 background diabetic retinopathy 29.4 VEGFB VEGFA PGF KDR
23 ischemia 29.3 VEGFA PLG KDR FLT1 FGF2
24 myopia 29.3 VEGFA TGFB2 MYOC FGF2 CRYAA
25 capillary hemangioma 29.3 VEGFA KDR FLT1 FGF2
26 moyamoya disease 1 29.2 VEGFA PLG KDR FGF2
27 macular retinal edema 29.1 VEGFB VEGFA TJP1 PGF KDR FLT1
28 diabetes mellitus 29.0 VEGFA UCP2 PGF KDR FLT1 FGF2
29 retinal vascular occlusion 28.6 VEGFB VEGFA PLG PGF KDR FLT1
30 retinal vascular disease 28.6 VEGFB VEGFA PLG PGF KDR FLT1
31 eye disease 28.4 VEGFA TGFB2 RS1 PGF MYOC KDR
32 hypertension, essential 28.3 VEGFA UCP2 PLG PGF KDR FLT1
33 kuhnt-junius degeneration 28.2 VEGFD VEGFB VEGFA PLG PGF KDR
34 retinitis pigmentosa 28.2 VEGFA TJP1 RS1 MYOC KDR FGF2
35 macular degeneration, age-related, 1 27.1 VEGFD VEGFB VEGFA TJP1 TGFB2 RS1
36 retinoschisis 1, x-linked, juvenile 11.2
37 central retinal vein occlusion 10.8
38 microvascular complications of diabetes 2 10.8
39 retinal ischemia 10.6
40 blind hypotensive eye 10.5
41 yemenite deaf-blind hypopigmentation syndrome 10.4
42 carotid stenosis 10.4
43 melanoma 10.4
44 bullous retinoschisis 10.3 VEGFA RS1
45 corneal edema 10.3
46 vasculitis 10.3
47 fuchs' heterochromic uveitis 10.3 TGFB2 CXCL8
48 neuroretinitis 10.3
49 neurofibromatosis 10.3
50 microcystic meningioma 10.3 VEGFA FLT1

Graphical network of the top 20 diseases related to Neovascular Glaucoma:



Diseases related to Neovascular Glaucoma

Symptoms & Phenotypes for Neovascular Glaucoma

Human phenotypes related to Neovascular Glaucoma:

58 31 (show all 16)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 glaucoma 58 31 obligate (100%) Obligate (100%) HP:0000501
2 visual loss 58 31 hallmark (90%) Very frequent (99-80%) HP:0000572
3 iris neovascularization 58 31 hallmark (90%) Very frequent (99-80%) HP:0011497
4 retinal vein occlusion 58 31 hallmark (90%) Very frequent (99-80%) HP:0012636
5 photophobia 58 31 frequent (33%) Frequent (79-30%) HP:0000613
6 abnormality of the optic nerve 58 31 frequent (33%) Frequent (79-30%) HP:0000587
7 visual acuity test abnormality 58 31 frequent (33%) Frequent (79-30%) HP:0030532
8 ocular hypertension 58 31 frequent (33%) Frequent (79-30%) HP:0007906
9 ocular pain 58 31 frequent (33%) Frequent (79-30%) HP:0200026
10 abnormality of central retinal artery 58 31 frequent (33%) Frequent (79-30%) HP:3000032
11 retinal vascular proliferation 58 31 occasional (7.5%) Occasional (29-5%) HP:0007850
12 abnormal anterior chamber morphology 58 31 occasional (7.5%) Occasional (29-5%) HP:0000593
13 corneal stromal edema 58 31 occasional (7.5%) Occasional (29-5%) HP:0012040
14 retinal detachment 58 31 very rare (1%) Very rare (<4-1%) HP:0000541
15 abnormal uvea morphology 58 Frequent (79-30%)
16 abnormality of the posterior segment of the globe 58 Occasional (29-5%)

Symptoms:

12
  • progressive peripheral vision loss

MGI Mouse Phenotypes related to Neovascular Glaucoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.85 FGF2 FLT1 KDR PGF PLG TGFB2
2 nervous system MP:0003631 9.65 FGF2 FLT1 KDR PLG RS1 TGFB2
3 vision/eye MP:0005391 9.32 FGF2 FLT1 KDR MYOC PGF PLG

Drugs & Therapeutics for Neovascular Glaucoma

Drugs for Neovascular Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 30)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ranibizumab Approved Phase 4 347396-82-1 459903
2
Bevacizumab Approved, Investigational Phase 4 216974-75-3
3 Angiogenesis Inhibitors Phase 4
4 Antineoplastic Agents, Immunological Phase 4
5
Triamcinolone Approved, Vet_approved Phase 2, Phase 3 124-94-7 31307
6 Insulin, Globin Zinc Phase 2, Phase 3
7 insulin Phase 2, Phase 3
8 Anti-Inflammatory Agents Phase 2, Phase 3
9 Immunosuppressive Agents Phase 2, Phase 3
10 Hormones Phase 2, Phase 3
11 Hormone Antagonists Phase 2, Phase 3
12 Triamcinolone hexacetonide Phase 2, Phase 3
13 triamcinolone acetonide Phase 2, Phase 3
14 glucocorticoids Phase 2, Phase 3
15 Triamcinolone diacetate Phase 2, Phase 3
16 Immunologic Factors Phase 2, Phase 3
17 Mitomycins Phase 3
18 Mitogens Phase 3
19 Endothelial Growth Factors Phase 3
20 Anesthetics Phase 2
21 Pharmaceutical Solutions Phase 2
22 Antibiotics, Antitubercular Phase 2
23 Alkylating Agents Phase 2
24 Anti-Bacterial Agents Phase 2
25 Immunoglobulins Phase 1
26 Antibodies, Monoclonal Phase 1
27 Antibodies Phase 1
28
Racepinephrine Approved 329-65-7 838
29
Epinephrine Approved, Vet_approved 51-43-4 5816
30 Epinephryl borate

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Intravitreous Ranibizumab as Adjunctive Treatment for Trabeculectomy in Neovascular Glaucoma Completed NCT01922154 Phase 4 intravitreal ranibizumab
2 Intravitreal Ranibizumab Injection as Adjuvant in the Treatment of Postvitrectomy Diabetic Vitreous Hemorrhage Accompanied by Neovascular Glaucoma Completed NCT02647515 Phase 4 ranibizumab
3 The RAVE (Rubeosis Anit-VEgf) Trial, Utilizes Monthly Intravitreal Bevazizumab (Avastin) Injections for 12 Months to See if Total VEGF Blockade Will Prevent Neovascular Glaucoma and Eliminate the Need for Panretinal Photocoagulation in Patients With Ischemic Central Retinal Vein Occlusion Completed NCT00557232 Phase 4 bevacizumab
4 Intravitreal Ranibizumab (Lucentis®) for Neovascular Glaucoma- a Randomized Controlled Study Unknown status NCT02914626 Phase 3 Intravitreal ranibizumab
5 Prospective, Randomised, Placebo-controlled, Double-masked, Three-armed Multi-centre Trial of Aganirsen Versus Vehicle in Patients After Ischaemic Central Retinal Vein Occlusion With a High Risk to Develop Neovascular Glaucoma Unknown status NCT02947867 Phase 2, Phase 3 aganirsen
6 The Effect of Intracameral Triesence (Triamcinolone Acetonide Injectable Suspension) on Ocular Inflammation After Trabeculectomy, Tube Shunt Implantation or Combined Trabeculectomy With Cataract Surgery Completed NCT00853905 Phase 2, Phase 3 Triesence;balanced salt solution BSS
7 A Randomized, Double-masked, and Controlled Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerability of Intravitreal Administration of Aflibercept in Japanese Patients With Neovascular Glaucoma Completed NCT02396316 Phase 3 Aflibercept (Eylea, BAY 86-5321);Sham Injection
8 A Single-arm, Non-randomized and Open-label Phase 3 Study Evaluating the Efficacy, Safety and Tolerability of Intravitreal Aflibercept in Japanese Patients With Neovascular Glaucoma (NVG) Completed NCT03639675 Phase 3 Aflibercept (EYLEA, BAY86-5321);Topical IOP-lowering drugs
9 Comprative Study of the Safety and Effectiveness Between Oculusgen (Ologen) Collagen Matrix Implant and Mitomycin-C in Glaucoma Filtering Surgery Completed NCT00524758 Phase 3 MMC in Trabeculectomy
10 An Open-label Extended Clinical Protocol of Ranibizumab to Evaluate Safety and Efficacy in Rare VEGF Driven Ocular Diseases. Completed NCT01908816 Phase 3 ranibizumab
11 Prevention of Neovascular Glaucoma by Intravitreal Injections of Anti-Vascular Endothelial Growth Factor in Patients Treated With Proton Therapy for a Large Choroidal Melanoma Not yet recruiting NCT03172299 Phase 3 Aflibercept Injection;False injection
12 Analysis of Vitreous and Aqueous Humor for Ocular Growth Factors, Cytokines, Chemokines, and Ranibizumab Pharmacokinetics Associated With Various Retinal Disease Unknown status NCT02067013 Phase 2 Ranibizumab
13 Avastin as an Adjunct to Diode Laser Cyclophotoablation in the Treatment of Neovascular Glaucoma Completed NCT01051583 Phase 2
14 Ahmed Glaucoma Valve Surgery With Mitomycin-C Active, not recruiting NCT02805257 Phase 2 Mitomycin-C
15 Randomized Controlled Trial of Lucentis in the Management of New Onset Neovascular Glaucoma Withdrawn NCT00727038 Phase 1, Phase 2 Ranibizumab (Lucentis)
16 A Phase I Single Center Study of Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma Completed NCT00765921 Phase 1 ranibizumab
17 Comparative Study of the Safety and Efficacy of the Ahmed Glaucoma Valve Drainage Device, Model M4 (High Density Porous Polyethylene) and the Model S2 (Polypropylene) in Patients With Neovascular Glaucoma Unknown status NCT02260219
18 Comparison of Efficacy Between Silicone Ahmed Glaucoma Valves With and Without Intravitreal Triamcinolone Injection Unknown status NCT00491712
19 An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma Completed NCT01370135 0.5mg intraocular Ranibizumab (Lucentis)
20 The Effect of Conbercept Injection Through Different Routes for Neovascular Glaucoma Completed NCT03154892
21 Use of Intravitreal Aflibercept Injection for Neovascular Glaucoma Completed NCT01711879 Aflibercept
22 Intravitreal Bevacizumab for Neovascular Glaucoma; a Randomized Placebo Controlled Clinical Trial Completed NCT00384631 Avastin
23 Triple Procedure for Dense Cataractus Neovascular Glaucoma Patients Completed NCT04143620
24 Baerveldt Glaucoma Implant Versus Ahmed Glaucoma Implant in One- Year Follow up, Comparative Study Completed NCT04215575
25 One- Year Follow up of Two Models of Ahmed Glaucoma Valves (S2 and FP7) in Refractory Glaucoma Completed NCT04214847
26 Treatment Outcomes of MicroPulse Trans-scleral Cyclophotocoagulation (mTSCPC) in Uncontrolled Glaucoma at the University of Montreal Hospital Center (CHUM) Completed NCT03187418
27 A Randomized Trial of the Pops-titration Versus the Slow-coagulation Energy Delivery Technique on the Outcome of Diode Laser Transcleral Cyclophotocoagulation in Treatment of Neovascular Glaucoma With Dark Iris Completed NCT01774227
28 Drug Use Investigation for Eylea for Neovascular Glaucoma (NVG) Recruiting NCT04519619 Aflibercept (Eylea, BAY86-5321)
29 Efficacy and Safety of Intracameral Versus Intravitreal Bevacizumab Injection as an Adjunctive Therapy Before Trabeculectomy With Mitomycin-C in Neovascular Glaucoma: A Prospective Randomized Trial Recruiting NCT03648814
30 INTEGRAL Study: A Longitudinal Study of Surgeries and Lasers in Glaucoma: Long-term Results and Success Predictors Analysed From a Large-scale Retrospective and Prospective Glaucoma Register Recruiting NCT04381611
31 Comparison of Porcine Submucosal Tissue Patch Graft (KeraSys) Versus Processed Pericardium Patch Graft (Tutoplast) in Glaucoma Drainage Implant Surgery Using a Molteno 3 Shunt Terminated NCT01301378
32 Effects of Travoprost on Neovascular Glaucoma Withdrawn NCT00441181 Travoprost

Search NIH Clinical Center for Neovascular Glaucoma

Cochrane evidence based reviews: glaucoma, neovascular

Genetic Tests for Neovascular Glaucoma

Anatomical Context for Neovascular Glaucoma

MalaCards organs/tissues related to Neovascular Glaucoma:

40
Eye, Endothelial, Retina, Myeloid, Kidney, Pancreas, Breast

Publications for Neovascular Glaucoma

Articles related to Neovascular Glaucoma:

(show top 50) (show all 1657)
# Title Authors PMID Year
1
Aqueous humor endothelin-1 (Et-1), vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2) levels in Mexican glaucomatous patients. 61 54
20373895 2010
2
Concentration of vascular endothelial growth factor after intracameral bevacizumab injection in eyes with neovascular glaucoma. 61 54
19794946 2009
3
Level of vascular endothelial growth factor in aqueous humor and surgical results of ahmed glaucoma valve implantation in patients with neovascular glaucoma. 61 54
19680051 2009
4
Intracameral bevacizumab effectively reduces aqueous vascular endothelial growth factor concentrations in neovascular glaucoma. 54 61
18617542 2009
5
Intravitreal bevacizumab (Avastin) injection for neovascular glaucoma. 54 61
17700285 2007
6
[The change of the level of the vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma before and after anterior retinal cryotherapy]. 61 54
17897552 2007
7
[Inhibition of angiogenesis in the anterior chamber of the eye]. 54 61
17372736 2007
8
Increased levels of transforming growth factor-betal and -beta2 in the aqueous humor of patients with neovascular glaucoma. 54 61
17278530 2007
9
Transforming growth factor-beta levels in human aqueous humor of glaucomatous, diabetic and uveitic eyes. 54 61
17004630 2006
10
Vascular endothelial growth factor is increased in aqueous humor of glaucomatous eyes. 61 54
12362079 2002
11
Increased level of vascular endothelial growth factor in aqueous humor of patients with neovascular glaucoma. 61 54
9479280 1998
12
Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate. 61 54
8694732 1996
13
Neovascular glaucoma - A review. 61
33595466 2021
14
Development of neovascular glaucoma after intraocular surgery in Pierson syndrome. 61
33554690 2021
15
Neovascular glaucoma in patients with central retinal vein occlusion: A real-life study in the anti-VEGF era. 61
32548981 2021
16
Efficacy and Safety of Intravitreal Aflibercept Injection in Japanese Patients with Neovascular Glaucoma: Outcomes from the VENERA Study. 61
33330959 2021
17
Intravitreal Aflibercept in Japanese Patients with Neovascular Glaucoma: The VEGA Randomized Clinical Trial. 61
33330958 2021
18
Intravitreal anti-vascular endothelial growth factor medications during pregnancy: current perspective. 61
33044671 2021
19
Rubeosis iridis and macular hemorrhages from multiple Corkscrew retinal vessels in a patient with NF1. 61
33601906 2021
20
Robotic assisted CyberKnife radiosurgery for the treatment of choroidal metastasis. 61
33574560 2021
21
Hypofractionated stereotactic photon radiotherapy of choroidal melanoma: 20-year experience. 61
32969745 2021
22
Systematic Review and Meta-Analysis on the Use of Photon-based Stereotactic Radiosurgery Versus Fractionated Stereotactic Radiotherapy for the Treatment of Uveal Melanoma. 61
33208706 2021
23
Experience with Intravitreal Ranibizumab as an Adjunct to Ablation Therapy in Eyes with Exudative Coats' Disease. 61
33542620 2021
24
Juxtapapillary retinal capillary hemangioma: A clinical and histopathological case report. 61
33485171 2021
25
Dose-Response and Normal Tissue Complication Probabilities after Proton Therapy for Choroidal Melanoma. 61
32574763 2021
26
RETINAL NEOVASCULARIZATION FROM A PATIENT WITH CUTIS MARMORATA TELANGIECTATICA CONGENITA. 61
29543621 2021
27
RAPIDLY PROGRESSIVE NEOVASCULAR GLAUCOMA FROM CYTOMEGALOVIRUS RETINITIS IN A NON-HUMAN IMMUNODEFICIENCY VIRUS PATIENT. 61
29533389 2021
28
Trabecular Microbypass Stent and Phacoemulsification in African American Patients With Open-angle Glaucoma: Outcomes and Effect of Prior Laser Trabeculoplasty. 61
33351549 2021
29
Various modalities for management of secondary angle closure neovascular glaucoma in diabetic eyes: 1-year comparative study. 61
33387108 2021
30
Neovascular glaucoma. 61
33516571 2021
31
Successful stent implantation in the internal jugular vein occlusion using Brockenbrough needle under intravascular ultrasound guidance leading to prevention of vision loss in a hemodialysis patient with neovascular glaucoma. 61
33437331 2021
32
Altered spontaneous brain activity patterns in patients with neovascular glaucoma using amplitude of low-frequency fluctuations: A functional magnetic resonance imaging study. 61
33386699 2021
33
Chronic myeloid leukaemia accelerates proliferative retinopathy in patients with co-existent diabetes: A risk factor not to be ignored. 61
31514533 2021
34
Aqueous Inflammation and Ischemia-Related Biomarkers in Neovascular Glaucoma with Stable Iris Neovascularization. 61
32339463 2020
35
Radiation-induced neovascular glaucoma: A devastating disease. 61
33380681 2020
36
Use of laser iridoplasty in iris incarceration of a glaucoma drainage device. 61
32984651 2020
37
Optic nerve head sarcoidosis mimicking an intraocular tumour, and occurring as the first manifestation of neuro-ocular sarcoidosis. 61
33163694 2020
38
The incidence and risk factors of neovascular glaucoma secondary to proliferative diabetic retinopathy after vitrectomy. 61
33334171 2020
39
Anti-VEGF Therapy and Retinal Photocoagulation to Prevent Recurrence of Central Retinal Vein Occlusion: Two Case Reports of Young Patients. 61
33300598 2020
40
Endoscopic vitreoretinal surgery: Review of current applications and future trends. 61
33278403 2020
41
Proton beam irradiation of uveal melanoma involving the iris, ciliary body and anterior choroid without surgical localisation (light field). 61
33355171 2020
42
Trabeculectomy in patients with diabetes: subconjunctival Mitomycin C with or without intravitreal bevacizumab. 61
33328187 2020
43
Neovascular complications from cytomegalovirus necrotizing retinopathy in patients after haploidentical hematopoietic stem cell transplantation. 61
33323907 2020
44
Efficacy and safety of single Ultrasound Cyclo-Plasty to treat refractory glaucoma: Results at 1 year. 61
33225725 2020
45
A novel c.980C>G variant in OAT results in identifiable gyrate atrophy phenotype associated with retinal detachment in a young female. 61
33243052 2020
46
Central retinal artery and vein occlusion as a complication of persistent hyaloid artery - a case report. 61
33143669 2020
47
Characteristics and outcomes of vitrectomy for proliferative diabetic retinopathy in young versus senior patients. 61
33076873 2020
48
Profiles and Clinical Characteristics of Newly Diagnosed Glaucoma in Urban Korea: A Multicenter Study. 61
33099556 2020
49
Severe Neovascular Glaucoma Exacerbation as a Complication of Carotid Artery Stenting: A Case Report. 61
32983351 2020
50
Trend of Neovascular Glaucoma in Taiwan: A 15-year Nationwide Population-based Cohort Study. 61
32326791 2020

Variations for Neovascular Glaucoma

Expression for Neovascular Glaucoma

Search GEO for disease gene expression data for Neovascular Glaucoma.

Pathways for Neovascular Glaucoma

Pathways related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 45)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.79 VEGFD VEGFB VEGFA TGFB2 PGF KDR
2
Show member pathways
13.66 VEGFD VEGFB VEGFA TGFB2 PGF KDR
3
Show member pathways
13.52 VEGFD VEGFB VEGFA TGFB2 PGF KDR
4
Show member pathways
13.49 VEGFD VEGFB TGFB2 PGF KDR FLT1
5
Show member pathways
13.39 VEGFD VEGFB TGFB2 PGF KDR FLT1
6
Show member pathways
13.29 VEGFD VEGFB TGFB2 PGF KDR FLT1
7
Show member pathways
13.27 VEGFD VEGFB TJP1 TGFB2 PGF KDR
8
Show member pathways
13.25 VEGFD VEGFB VEGFA TGFB2 PGF KDR
9
Show member pathways
13.05 VEGFD VEGFB TGFB2 PGF KDR FLT1
10
Show member pathways
13.03 VEGFD VEGFB TGFB2 PGF KDR FLT1
11
Show member pathways
12.97 VEGFD VEGFB VEGFA PGF KDR FLT1
12
Show member pathways
12.9 VEGFD VEGFB VEGFA PGF KDR FLT1
13 12.84 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
14
Show member pathways
12.72 TGFB2 PLG KDR FGF2 CAPN5
15
Show member pathways
12.7 VEGFD VEGFB VEGFA PGF KDR FLT1
16
Show member pathways
12.64 VEGFD VEGFB TGFB2 PGF KDR FLT1
17 12.59 VEGFD VEGFB VEGFA TGFB2 PGF KDR
18
Show member pathways
12.55 VEGFA TGFB2 KDR FGF2
19
Show member pathways
12.5 VEGFB VEGFA KDR FLT1 FGF2
20
Show member pathways
12.43 VEGFD VEGFB VEGFA PGF KDR FLT1
21
Show member pathways
12.4 VEGFD VEGFB TGFB2 PGF KDR FLT1
22
Show member pathways
12.39 VEGFD VEGFB VEGFA KDR FLT1 FGF2
23 12.38 VEGFD VEGFB VEGFA KDR FLT1 FGF2
24 12.29 VEGFA TGFB2 KDR FGF2
25 12.13 VEGFB KDR FLT1 FGF2
26
Show member pathways
11.93 VEGFA KDR FLT1
27 11.92 VEGFA FGF2 CXCL8
28 11.89 VEGFA TGFB2 FLT1 CXCL8
29 11.89 VEGFD VEGFB VEGFA TGFB2 CXCL8
30
Show member pathways
11.82 VEGFB VEGFA PGF KDR FLT1
31 11.78 VEGFB TGFB2 KDR FLT1 FGF2
32
Show member pathways
11.77 VEGFD VEGFB TGFB2 PGF KDR FLT1
33 11.73 VEGFD VEGFB TGFB2 PGF FGF2
34 11.7 VEGFA TGFB2 KDR FLT1
35 11.67 VEGFA TGFB2 FGF2
36 11.58 VEGFD VEGFB VEGFA
37 11.5 VEGFA KDR FGF2
38 11.36 VEGFA KDR FLT1
39 11.34 VEGFA TGFB2 PLG KDR FGF2
40 11.22 VEGFA FLT1 FGF2
41 11.19 VEGFB VEGFA KDR FLT1 FGF2
42 11.09 VEGFA KDR FLT1 FGF2
43 10.87 VEGFD VEGFB TGFB2 PGF KDR FLT1
44 10.64 VEGFB VEGFA
45
Show member pathways
10.3 VEGFD VEGFB VEGFA PGF KDR FLT1

GO Terms for Neovascular Glaucoma

Cellular components related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.9 VEGFD VEGFB VEGFA TGFB2 RS1 PLG
2 extracellular region GO:0005576 9.73 VEGFD VEGFB VEGFA TGFB2 RS1 PLG
3 platelet alpha granule lumen GO:0031093 9.02 VEGFD VEGFB VEGFA TGFB2 PLG

Biological processes related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

(show all 42)
# Name GO ID Score Top Affiliating Genes
1 multicellular organism development GO:0007275 10.17 VEGFD VEGFA RS1 PGF KDR FLT1
2 cell differentiation GO:0030154 10.15 VEGFD VEGFA PGF KDR FLT1 FGF2
3 positive regulation of cell proliferation GO:0008284 10.1 VEGFD VEGFA TJP1 TGFB2 PGF KDR
4 negative regulation of apoptotic process GO:0043066 10.07 VEGFB VEGFA UCP2 TJP1 KDR CRYAA
5 negative regulation of gene expression GO:0010629 10.03 VEGFB VEGFA TGFB2 KDR FGF2 CXCL8
6 positive regulation of protein phosphorylation GO:0001934 10 VEGFD VEGFB VEGFA PGF KDR FGF2
7 response to hypoxia GO:0001666 9.99 VEGFD VEGFB VEGFA UCP2 TGFB2 PGF
8 positive regulation of cell migration GO:0030335 9.97 VEGFA TJP1 MYOC KDR FLT1
9 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.96 VEGFB VEGFA KDR FGF2
10 positive regulation of protein kinase B signaling GO:0051897 9.95 VEGFB VEGFA MYOC FGF2
11 platelet degranulation GO:0002576 9.95 VEGFD VEGFB VEGFA TGFB2 PLG
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.93 VEGFA TGFB2 MYOC KDR FLT1 FGF2
13 angiogenesis GO:0001525 9.92 VEGFD VEGFB VEGFA PGF KDR FLT1
14 positive regulation of MAPK cascade GO:0043410 9.9 VEGFA KDR FLT1 FGF2
15 positive chemotaxis GO:0050918 9.88 VEGFD VEGFB VEGFA PGF FGF2
16 positive regulation of endothelial cell proliferation GO:0001938 9.88 VEGFD VEGFB VEGFA PGF KDR FGF2
17 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.85 VEGFD VEGFB VEGFA PGF KDR FLT1
18 sprouting angiogenesis GO:0002040 9.84 VEGFD VEGFB VEGFA PGF
19 positive regulation of endothelial cell migration GO:0010595 9.83 VEGFA KDR FGF2
20 positive regulation of MAP kinase activity GO:0043406 9.83 VEGFA FLT1 FGF2
21 positive regulation of blood vessel endothelial cell migration GO:0043536 9.81 VEGFA KDR FGF2
22 positive regulation of cell migration involved in sprouting angiogenesis GO:0090050 9.79 VEGFA KDR FGF2
23 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.79 VEGFA KDR FLT1
24 positive regulation of sprouting angiogenesis GO:1903672 9.78 VEGFA TJP1 FGF2
25 positive regulation of focal adhesion assembly GO:0051894 9.76 VEGFA MYOC KDR
26 cell migration involved in sprouting angiogenesis GO:0002042 9.74 VEGFA KDR FGF2
27 positive regulation of mast cell chemotaxis GO:0060754 9.73 VEGFD VEGFB VEGFA PGF
28 positive regulation of cell division GO:0051781 9.73 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
29 embryonic morphogenesis GO:0048598 9.69 FLT1 FGF2
30 embryonic digestive tract development GO:0048566 9.68 TGFB2 CXCL8
31 positive regulation of DNA biosynthetic process GO:2000573 9.68 VEGFA FGF2
32 positive regulation of phospholipase C activity GO:0010863 9.68 FLT1 FGF2
33 positive regulation of positive chemotaxis GO:0050927 9.68 VEGFA KDR
34 negative regulation of cell-cell adhesion mediated by cadherin GO:2000048 9.67 VEGFA PLG
35 positive regulation of mitochondrial depolarization GO:0051901 9.67 MYOC KDR
36 vascular wound healing GO:0061042 9.66 VEGFA KDR
37 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.64 VEGFA KDR
38 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.64 VEGFA KDR
39 positive regulation of epithelial tube formation GO:1905278 9.62 VEGFA FGF2
40 positive regulation of angiogenesis GO:0045766 9.56 VEGFD VEGFB VEGFA PGF KDR FLT1
41 induction of positive chemotaxis GO:0050930 9.55 VEGFD VEGFB VEGFA PGF CXCL8
42 vascular endothelial growth factor signaling pathway GO:0038084 9.1 VEGFD VEGFB VEGFA PGF KDR FLT1

Molecular functions related to Neovascular Glaucoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.71 VEGFA TGFB2 FGF2 CXCL8
2 growth factor activity GO:0008083 9.63 VEGFD VEGFB VEGFA TGFB2 PGF FGF2
3 heparin binding GO:0008201 9.62 VEGFB VEGFA PGF FGF2
4 platelet-derived growth factor receptor binding GO:0005161 9.43 VEGFD VEGFA
5 vascular endothelial growth factor-activated receptor activity GO:0005021 9.37 KDR FLT1
6 chemoattractant activity GO:0042056 9.35 VEGFD VEGFB VEGFA PGF FGF2
7 vascular endothelial growth factor receptor 1 binding GO:0043183 9.26 VEGFB VEGFA
8 vascular endothelial growth factor receptor binding GO:0005172 8.92 VEGFD VEGFB VEGFA PGF

Sources for Neovascular Glaucoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....